-
1
المصدر: Фармакоэкономика, Vol 8, Iss 2, Pp 55-61 (2015)
مصطلحات موضوعية: linagliptin, medicine.medical_specialty, endocrine system diseases, type 2 diabetes mellitus, Population, alogliptin, RM1-950, Saxagliptin, Linagliptin, clinical safety, sitagliptin, law.invention, chemistry.chemical_compound, clinical efficacy, Randomized controlled trial, law, Internal medicine, medicine, Vildagliptin, saxagliptin, education, HB71-74, Pharmacology, education.field_of_study, business.industry, Health Policy, Public Health, Environmental and Occupational Health, systematic literature review, nutritional and metabolic diseases, Metformin, Endocrinology, Economics as a science, chemistry, indirect comparison, vildagliptin, Sitagliptin, Therapeutics. Pharmacology, business, dipeptidyl peptidase-4 inhibitors, Alogliptin, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67eb92383948a8f5ae5a1987baa5bcb
https://www.pharmacoeconomics.ru/jour/article/view/105